TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28809637
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for subcapital ulnar fractures.
Study: 28809637
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for ulnar head fractures.
Study: 24529671
Drug: bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 10 mg combined with 0.1 mg/kg ketamine
Study: 24529671
Drug: bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 10 mg combined with 0.5 mL distilled water
Study: 23525044
Drug: Levodopa (L-DOPA)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (L-DOPA)
Study: 9444592
Drug: Full-strength oxidizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength oxidizing lozenge
Study: 9444592
Drug: Regular oxidizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular oxidizing lozenge
Study: 3284282
Drug: Contingency contracting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency contracting for medication take-home privileges
Study: 3284282
Drug: Contingency contracting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency contracting targeting non-cocaine drugs
Study: 3284282
Drug: Non-drug-related contracts
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug-related contracts
Study: 31465756
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus dry needling (Ex+DN group)
Study: 31465756
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (Ex group)
Study: 27334604
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (group 1, n=76)
Study: 21611981
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 1200 mg once daily
Study: 15159270
Drug: niacin ER/lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin ER/lovastatin (1500/20 mg)
Study: 15159270
Drug: niacin ER/lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin ER/lovastatin (2000/40 mg)
Study: 15159270
Drug: niacin ER
Normalized name: Niacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin ER (each 500 mg increase)
Study: 15159270
Drug: niacin ER/lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin ER/lovastatin (2000/40 mg/d)
Study: 9737476
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg twice daily subcutaneously)
Study: 9737476
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (continuous intravenous)
Study: 7887165
Drug: Local specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local specific immunotherapy plus sodium cromoglycate
Study: 7887165
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate and saline solution
Study: 3580432
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg RS 86
Study: 3580432
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg RS 86
Study: 31821221
Drug: NEW Tx
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEW Tx (Nutrition Exercise and Wellness Treatment)
Study: 30875669
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment as usual waitlist)
Study: 28527047
Drug: Dietary ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary ascorbic acid (50 mg/kg)
Study: 28527047
Drug: Dietary ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary ascorbic acid (100 mg/kg)
Study: 9544237
Drug: Intravenous gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma globulin (IVIG) therapy
Study: 7541325
Drug: rhG-CSF (Granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG-CSF (Granulocyte Injection) with chemotherapy
Study: 3824375
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg four times daily
Study: 17407633
Drug: EZE +
Normalized name: Acetaminophen 650 MG Oral Tablet [PAIN-EZE +/RHEU-THRITIS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE + ATV (Ezetimibe 10 mg + Atorvastatin 10 mg)
Study: 17407633
Drug: ATV (Atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV (Atorvastatin 10 mg)
Study: 11095203
Drug: 15% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% glycolic acid cream used once or twice daily for 24 weeks by 20 patients in Group B
Study: 11095203
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 24 weeks by 15 patients in Group C
Study: 9506004
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg anhydrous, oral administration)
Study: 8456071
Drug: Fast-disintegrating vitamin
Normalized name: vitamin B12 Disintegrating Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-disintegrating vitamin C tablet (8-9 min)
Study: 8456071
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C tablet with a mean disintegration time of 60 min
Study: 8456071
Drug: Standard vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vitamin C solution
Study: 2416520
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment (1 g/day) for four weeks (standard treatment group)
Study: 2416520
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment (1 g/day) for a minimum of one week and thereafter until symptoms controlled (symptomatic treatment group)
Study: 2416520
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens (standard and symptomatic)
Study: 2416520
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment group
Study: 28922046
Drug: Supraorbital electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supraorbital electrical stimulation (SOES) in addition to conventional physical therapy (20 minutes daily for 8 weeks)
Study: 28922046
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (3 times a week for 8 weeks)
Study: 28922046
Drug: Prescribed medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed medications only
Study: 17076946
Drug: Oral polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polyethylene glycol (PEG)
Study: 22137497
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (300 μg daily)
Study: 15781540
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% plus clonidine 2 microg/mL
Study: 14519752
Drug: Screened arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screened arm (prostate-specific antigen, digital rectal and transrectal ultrasound examinations)
Study: 31853960
Drug: Lebrikizumab (anti-IL-13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab (anti-IL-13 monoclonal antibody)
Study: 22311411
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy (CT) combining EA and PI for 40 days.
Study: 9272472
Drug: Chiropractic management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic management (spinal manipulation, soft tissue therapy, passive stretching for 4 weeks)
Study: 3205676
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (tablets)
Study: 1972334
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg kg‐1 as a bolus (n = 10)
Study: 31189287
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate and benzydamine hydrochloride solution
Study: 31189287
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and phosphate solution
Study: 31189287
Drug: Black mulberry
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black mulberry syrup
Study: 19439506
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with thyroid hormone (TH) including thyroxine and T(3) in prolonged critically ill rabbits
Study: 17574679
Drug: Endothelial progenitor
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial progenitor cells (EPCs) therapy
Study: 16328638
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of oral celecoxib administered 30 min before surgery
Study: 7950168
Drug: rHuEPO 150
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO 150 U/kg s.c. once daily for two consecutive days
Study: 7950168
Drug: rHuEPO 150
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO 150 U/kg i.v. once daily for two consecutive days
Study: 2823313
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LTB4 and PGE2
Study: 28448398
Drug: 150 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg/kg EREM
Study: 28448398
Drug: 7.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg/kg IT morphine
Study: 23758655
Drug: Primary surgery
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary surgery followed by adjuvant chemotherapy (6 cycles of Epirubicin, cisplatin, 5-fluorouracil)
Study: 23758655
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (2x3 cycles of Epirubicin, cisplatin, 5-fluorouracil)
Study: 21963186
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment during spontaneous breathing via a thin catheter
Study: 18342224
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimal medical therapy without hemodynamic monitoring)
Study: 11303053
Drug: Celecoxib in
Normalized name: Product containing celecoxib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib in solution
Study: 11303053
Drug: Celecoxib in
Normalized name: Product containing celecoxib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib in capsule
Study: 11303053
Drug: Celecoxib intragastrically
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib intragastrically in solution
Study: 9076853
Drug: No psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: No psychiatric treatment group
Study: 25347968
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 75.4 g kg(‐1) lipid level
Study: 25347968
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 51.4 g kg(‐1) lipid level
Study: 10917072
Drug: Class II
Normalized name: HLA class II antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class II agents (beta-blockers)
Study: 8371471
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I antiarrhythmic agents
Study: 9114762
Drug: d,l-sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-sotalol
Study: 10917072
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (class IV agents)
Study: 1904750
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ritanserin
Study: 28039798
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (5-week supply)
Study: 22225544
Drug: Probiotic-enriched artichokes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-enriched artichokes (180 g per day, 2 × 10(10) CFU of Lactobacillus paracasei IMPC 2.1)
Study: 20128566
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intravitreal dexamethasone
Study: 20128566
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg intravitreal dexamethasone
Study: 17585971
Drug: 150 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/kg TYR (total 300 mg/kg)
Study: 15750360
Drug: Homeopathic combination
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic combination medicine
Study: 11876695
Drug: Pantoprazole, 40
Normalized name: Pantoprazole, 40 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, 40 mg once daily
Study: 1673233
Drug: bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol 10 mg o.d.
Study: 1673233
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg o.d.
Study: 324577
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for mild hypertension
Study: 24861837
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy with TCM
Study: 24067192
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (50, 150, or 300 mg/day)
Study: 18612923
Drug: Etanercept in
Normalized name: etanercept Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept in combination with methotrexate (MTX)
Study: 11847165
Drug: No ACE
Normalized name: Amino Acetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE inhibitor treatment (Control)
Study: 1790147
Drug: Recombinant gamma-interferon
Normalized name: gamma-interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant gamma-interferon (rGIFN) as a 2-h intravenous infusion daily x 5 every other week at a starting dose of 4.0 x 10(6) IU/m2/day (arm I)
Study: 1790147
Drug: Recombinant gamma-interferon
Normalized name: gamma-interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant gamma-interferon (rGIFN) as a 24-h continuous intravenous infusion daily x 5 every month at a starting dose of 2.6 x 10(6) IU/m2/day (arm II)
Study: 27807735
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg body weight oral GHB before going to bed
Study: 21362312
Drug: Shensongyangxin (SSYX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shensongyangxin (SSYX) capsule
Study: 21362312
Drug: Mexiletine tablet
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mexiletine tablet
Study: 16905632
Drug: New generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generation antipsychotics (amisulpride)
Study: 16905632
Drug: New generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generation antipsychotics (olanzapine)
Study: 16905632
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics (CAs)
Study: 15070934
Drug: Cabergoline treatment
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline treatment for 24 months
Study: 10989854
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg rocuronium
Study: 11455866
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg vecuronium
Study: 2310658
Drug: 10% glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycerol in saline (500 ml over 4 h on 6 consecutive days)
Study: 15055892
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with saline
Study: 28512921
Drug: Integrated Bipolar
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Bipolar Parenting Intervention (IBPI) plus treatment as usual (TAU)
Study: 25557952
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg/day) and Sofosbuvir (400 mg/day)
Study: 25557952
Drug: Peginterferon alfa
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa 2b (1.5 mcg/kg/wk), Ribavirin (1000-1200 mg/day), and Sofosbuvir (400 mg/day)
Study: 15564951
Drug: Prophylactic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic epidural blood patch with 20 ml autologous blood
Study: 7802571
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic therapy)
Study: 3292578
Drug: Muscle stretching
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle stretching treatment
Study: 30376130
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg EOW)
Study: 31713184
Drug: Calcitriol 0.25
Normalized name: CALCITRIOL 0.25MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.25 μg three times daily from transplantation to day 30
Study: 24284618
Drug: Sublingual nucleotides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nucleotides (50 mg/day) for 14 days
Study: 21766553
Drug: L-isoleucine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-isoleucine (2 g/L)-added ORS
Study: 21766553
Drug: ORS without
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS without L-isoleucine (control)
Study: 8380295
Drug: NWTS-1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NWTS-1 treatment regimen
Study: 8380295
Drug: NWTS-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NWTS-2 treatment regimen
Study: 8380295
Drug: NWTS-3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NWTS-3 treatment regimen
Study: 8380295
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with specimen weight 550 g or greater
Study: 3946161
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.25 mg/kg)
Study: 3946161
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.25 mg/kg) in patients receiving long-term propranolol (120 to 240 mg/day)
Study: 23104611
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections
Study: 23104611
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections
Study: 23104611
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Study: 23104611
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Study: 2589654
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (100 mg)
Study: 12670813
Drug: Morphine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (3 mg)
Study: 12670813
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (100 mg) + Morphine (3 mg)
Study: 10392225
Drug: Blood sample
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood sample obtained from normal saline lock after discarding 2 times the dead space (3 mL)
Study: 31652009
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation
Study: 31666344
Drug: R-HDS (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-HDS (high-dose chemotherapy with rituximab and autograft)
Study: 31666344
Drug: CHOP-R (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-R (conventional chemotherapy with rituximab)
Study: 22036059
Drug: Intrathecal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal dexamethasone (8 mg) with intrathecal morphine (0.2 mg)
Study: 22036059
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline solution with intrathecal morphine 0.2 mg)
Study: 20118683
Drug: 2-dose priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-dose priming with PHiD-CV
Study: 20118683
Drug: 3-dose priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-dose priming with PHiD-CV